Fibrate/Statin Initiation in Warfarin Users and Gastrointestinal Bleeding Risk

PURPOSE: To evaluate whether initiation of a fibrate or statin increases the risk of hospitalization for gastrointestinal bleeding in warfarin users. METHODS: We used Medicaid claims data (1999-2003) to perform an observational case-control study nested within person-time exposed to warfarin in those >= 18 years (n = 353,489). Gastrointestinal bleeding cases were matched to 50 controls based on index date and state. RESULTS: Chronic warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of gemfibrozil (1.88; 95% confidence interval [CI], 1.00-3.54] for the first prescription: 1.75; 95% CI, 0.77-3.95 for the second prescription); simvastatin (1.46; 95% CI, 1.03-2.07 for the first prescription; 1.60; 95% CI, 1.07-2.39 for the second prescription); or atorvastatin (1.39; 95% CI, 1.07-1.81 for the first prescription; 1.05; 95% CI, 0.73-1.52 for the second prescription). In contrast, no increased risk wits found with pravastatin initiation (0.75; 95% CI, 0.39-1.46 for the first prescription; 0.90; 95% CI, 0.43-1.91 for the second prescription). CONCLUSIONS: Initiation of a fibrate or statin, that inhibits CYP3A4 enzymes, including atorvastatin, was associated with an increased risk of hospitalization for gastrointestinal bleeding. Initiation of pravastatin, which is mainly excreted unchanged, was not associated with In increased risk. (C) 2010 Elsevier Inc. All rights reserved. . The American Journal of Medicine (2010) 123, 151-157